Literature DB >> 3009877

Immune responses to isolated human cytomegalovirus envelope proteins.

E Gönczöl, F Hudecz, J Ianacone, B Dietzschold, S Starr, S A Plotkin.   

Abstract

A group of envelope proteins of human cytomegalovirus, gA protein (L. Pereira, M. Hoffman, M. Tatsuno, and D. Dondero, Virology 139:73-86, 1984; L. Pereira, p. 383-404, in B. Roizman, ed., The herpesviruses, vol. 3, 1985), and two protein mixtures (58,000-molecular-weight [58K]-66K and 130K-66K), separated by serial columns prepared with anti-gA immunoglobulin G from sera of immunized guinea pigs, induced neutralizing antibodies and a cellular immune response in the animals. The gA is a disulfide-linked protein complex consisting of high-molecular-weight (greater than 200K), 130K-150K, and 55K-58K proteins.

Entities:  

Mesh：

Substances：

Year:  1986        PMID： 3009877      PMCID： PMC252959     

Source DB:  PubMed          Journal:  J Virol        ISSN： 0022-538X            Impact factor:   5.103


  15 in total

1.  Protein measurement with the Folin phenol reagent.

Authors:  O H LOWRY; N J ROSEBROUGH; A L FARR; R J RANDALL
Journal:  J Biol Chem       Date:  1951-11       Impact factor: 5.157

2.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

3.  Towne-vaccine-induced prevention of cytomegalovirus disease after renal transplants.

Authors:  S A Plotkin; M L Smiley; H M Friedman; S E Starr; G R Fleisher; C Wlodaver; D C Dafoe; A D Friedman; R A Grossman; C F Barker
Journal:  Lancet       Date:  1984-03-10       Impact factor: 79.321

4.  Localization and synthesis of an antigenic determinant of herpes simplex virus glycoprotein D that stimulates the production of neutralizing antibody.

Authors:  G H Cohen; B Dietzschold; M Ponce de Leon; D Long; E Golub; A Varrichio; L Pereira; R J Eisenberg
Journal:  J Virol       Date:  1984-01       Impact factor: 5.103

5.  Silver staining of proteins in polyacrylamide gels.

Authors:  W Wray; T Boulikas; V P Wray; R Hancock
Journal:  Anal Biochem       Date:  1981-11-15       Impact factor: 3.365

6.  "Western blotting": electrophoretic transfer of proteins from sodium dodecyl sulfate--polyacrylamide gels to unmodified nitrocellulose and radiographic detection with antibody and radioiodinated protein A.

Authors:  W N Burnette
Journal:  Anal Biochem       Date:  1981-04       Impact factor: 3.365

7.  HCMV envelope antigens induce both humoral and cellular immunity in guinea pigs.

Authors:  T Furukawa; E Gonczol; S Starr; M D Tolpin; A Arbeter; S A Plotkin
Journal:  Proc Soc Exp Biol Med       Date:  1984-02

8.  Characterization of monoclonal antibodies and polyclonal immune sera directed against human cytomegalovirus virion proteins.

Authors:  B Nowak; C Sullivan; P Sarnow; R Thomas; F Bricout; J C Nicolas; B Fleckenstein; A J Levine
Journal:  Virology       Date:  1984-01-30       Impact factor: 3.616

9.  Monoclonal antibodies to human cytomegalovirus: three surface membrane proteins with unique immunological and electrophoretic properties specify cross-reactive determinants.

Authors:  L Pereira; M Hoffman; D Gallo; N Cremer
Journal:  Infect Immun       Date:  1982-06       Impact factor: 3.441

10.  Neutralizing antibodies detect a disulfide-linked glycoprotein complex within the envelope of human cytomegalovirus.

Authors:  W J Britt
Journal:  Virology       Date:  1984-06       Impact factor: 3.616
View more
  11 in total

1.  Identification and characterization of three distinct families of glycoprotein complexes in the envelopes of human cytomegalovirus.

Authors:  D R Gretch; B Kari; L Rasmussen; R C Gehrz; M F Stinski
Journal:  J Virol       Date:  1988-03       Impact factor: 5.103

2.  Human immune responses to major human cytomegalovirus glycoprotein complexes.

Authors:  Y N Liu; B Kari; R C Gehrz
Journal:  J Virol       Date:  1988-03       Impact factor: 5.103

3.  Antigenic cross-reactions among herpes simplex virus types 1 and 2, Epstein-Barr virus, and cytomegalovirus.

Authors:  N Balachandran; D E Oba; L M Hutt-Fletcher
Journal:  J Virol       Date:  1987-04       Impact factor: 5.103

4.  Sequence requirements for proteolytic processing of glycoprotein B of human cytomegalovirus strain Towne.

Authors:  R R Spaete; A Saxena; P I Scott; G J Song; W S Probert; W J Britt; W Gibson; L Rasmussen; C Pachl
Journal:  J Virol       Date:  1990-06       Impact factor: 5.103

5.  Cell surface expression of human cytomegalovirus (HCMV) gp55-116 (gB): use of HCMV-recombinant vaccinia virus-infected cells in analysis of the human neutralizing antibody response.

Authors:  W J Britt; L Vugler; E J Butfiloski; E B Stephens
Journal:  J Virol       Date:  1990-03       Impact factor: 5.103

Review 6.  The history of vaccination against cytomegalovirus.

Authors:  Stanley Plotkin
Journal:  Med Microbiol Immunol       Date:  2015-03-20       Impact factor: 3.402

7.  Induction of complement-dependent and -independent neutralizing antibodies by recombinant-derived human cytomegalovirus gp55-116 (gB).

Authors:  W J Britt; L Vugler; E B Stephens
Journal:  J Virol       Date:  1988-09       Impact factor: 5.103

8.  Distribution of linear antigenic sites on glycoprotein gp55 of human cytomegalovirus.

Authors:  N Kniess; M Mach; J Fay; W J Britt
Journal:  J Virol       Date:  1991-01       Impact factor: 5.103

9.  Marek's disease virus serotype-1 antigens A and B and their unglycosylated precursors detected by Western blot analysis of infected cells.

Authors:  I Davidson; M Malkinson; Y Becker
Journal:  Virus Genes       Date:  1988-10       Impact factor: 2.332

10.  Identification and expression of a human cytomegalovirus glycoprotein with homology to the Epstein-Barr virus BXLF2 product, varicella-zoster virus gpIII, and herpes simplex virus type 1 glycoprotein H.

Authors:  M P Cranage; G L Smith; S E Bell; H Hart; C Brown; A T Bankier; P Tomlinson; B G Barrell; T C Minson
Journal:  J Virol       Date:  1988-04       Impact factor: 5.103
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.